

Financial news for AMRN dated on 2020-06-08: Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.

Financial news for AMRN dated on 2020-05-22: Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement

Financial news for AMRN dated on 2020-05-22: Amarin Corp shares are trading lower after Hikma Pharmaceuticals USA received FDA approval for its Icosapent Ethyl Capsules, the generic equivalent to Amarin's Vascepa.

Financial news for AMRN dated on 2020-05-22: Amarin Shares Lower After FDA Approval Hikma Pharmaceuticals Icosapent Ethyl Capsules, The Generic Equivalent To Amarin's Vascepa

Financial news for AMRN dated on 2020-05-22: 20 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AMRN dated on 2020-05-22: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetrphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Financial news for AMRN dated on 2020-05-21: 8 Stocks Moving In Thursday's After-Hours Session

Financial news for AMRN dated on 2020-05-21: Amarin shares are trading higher after the company announced support for a clinical trial to investigate the effects of VASCEPA on inflammatory biomarkers and other patient outcomes in individuals with COVID-19.

Financial news for AMRN dated on 2020-05-21: Amarin Reports Will Support Trial To Investigate Effects Of VASCEPA On Inflammatory Biomarkers, Other Patient Outcomes In Individuals With Coronavirus

Financial news for AMRN dated on 2020-05-18: Amarin Corp Option Alert: Aug 21 \$7 Puts at the Bid: 10000 @ \$1.0 vs 0 OI; Ref=\$7.495

Financial news for AMRN dated on 2020-05-14: Amarin Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-IT(r) Study

Financial news for AMRN dated on 2020-05-04: Aegis Capital Maintains Buy on Amarin Corp, Raises Price Target to \$11

Financial news for AMRN dated on 2020-05-04: SVB Leerink Maintains Outperform on Amarin Corp, Raises Price Target to \$9

Financial news for AMRN dated on 2020-04-30: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for AMRN dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for AMRN dated on 2020-04-30: A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Apple Earnings

Financial news for AMRN dated on 2020-04-29: Amarin Corp Option Alert: May 15 \$9 Calls Sweep (10) near the Ask: 415 @ \$0.69 vs 6459 OI; Earnings 5/13 After Close [est] Ref=\$8.11

Financial news for AMRN dated on 2020-04-27: Amarin shares are trading higher potentially due to a positive media article on the stock which highlighted paths forward for the company following a significant decline in share price last month.

Financial news for AMRN dated on 2020-04-16: Cramer Shares His Thoughts On Yext, Workday And More

Financial news for AMRN dated on 2020-04-14: Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for AMRN dated on 2020-04-14: The Daily Biotech Pulse: Amarin Reports Strong Q1 Vascepa Sales, BeiGene Aces Late-Stage Lung Cancer Study, Glaxo, Sanofi Strike COVID-19 Vaccine Partnership

Financial news for AMRN dated on 2020-04-13: BZ NOTE: Earlier 8-K Filing From Amarin Showed Prelim. Q1 Sales Figures But Did Not Include Bottom-Line Data; This Was Tagged Under 'Guidance' Category In Benzinga Pro Newsfeed

Financial news for AMRN dated on 2020-04-13: Amarin Sees Prelim. Q1 Sales \$150M vs \$129.31M Est.; Says Cash And Equivalents Were More Than \$620M As Of Mar. 31

Financial news for AMRN dated on 2020-04-13: Earnings Scheduled For April 13, 2020

Financial news for AMRN dated on 2020-04-12: The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates

Financial news for AMRN dated on 2020-04-09: Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further \$2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race.

Financial news for AMRN dated on 2020-04-08: Amarin Corp Option Alert: Jun 19 \$5 Calls at the Ask: 917 @ \$1.5 vs 2402 OI; Earnings 4/29 Before Open [est] Ref=\$5.795

Financial news for AMRN dated on 2020-04-08: Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.

Financial news for AMRN dated on 2020-04-07: Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for AMRN dated on 2020-04-07: 15 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AMRN dated on 2020-04-05: The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations

Financial news for AMRN dated on 2020-04-02: Cowen On Amarin Says Thinks A Sale Or CVR 'Makes Sense'

Financial news for AMRN dated on 2020-04-02: 'Amarin: The Possible Procedural Error In The District Court Judgment' -Earlier Seeking Alpha Blog Post From Avisol Capital Partners

Financial news for AMRN dated on 2020-04-02: 72 Biggest Movers From Yesterday

Financial news for AMRN dated on 2020-04-01: 10 Biotech Winners And Losers In Q1

Financial news for AMRN dated on 2020-04-01: Citigroup Maintains Buy on Amarin Corp, Lowers Price Target to \$6

Financial news for AMRN dated on 2020-04-01: 77 Biggest Movers From Yesterday

Financial news for AMRN dated on 2020-03-31: Mid-Afternoon Market Update: Dow Falls Over 100 Points; Amarin Shares Slide

Financial news for AMRN dated on 2020-03-31: 56 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AMRN dated on 2020-03-31: Mid-Day Market Update: SG Blocks Surges Following Q4 Results; Seanergy Maritime Shares Plummet

Financial news for AMRN dated on 2020-03-31: Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment

Financial news for AMRN dated on 2020-03-31: Mid-Morning Market Update: Markets Rise; McCormick Posts Mixed Q1 Results

Financial news for AMRN dated on 2020-03-31: Stifel Maintains Hold on Amarin Corp, Lowers Price Target to \$8

Financial news for AMRN dated on 2020-03-31: Benzinga's Top Upgrades, Downgrades For March 31, 2020

Financial news for AMRN dated on 2020-03-31: Oppenheimer Upgrades Amarin Corp to Perform

Financial news for AMRN dated on 2020-03-31: 10 Biggest Price Target Changes For Tuesday

Financial news for AMRN dated on 2020-03-31: The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions

Financial news for AMRN dated on 2020-03-31: 17 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AMRN dated on 2020-03-31: 40 Stocks Moving in Tuesday's Pre-Market Session

Financial news for AMRN dated on 2020-03-31: Goldman Sachs Downgrades Amarin Corp to Neutral, Lowers Price Target to \$4

Financial news for AMRN dated on 2020-03-31: Amarin shares are trading lower after the company announced the FDA did not approve the abbreviated new drug applications for the company's VASCEPA capsule.

Financial news for AMRN dated on 2020-03-31: Matinas BioPharma Says US District Court Invalidity Decision On Amarin's Vascepa Patents Has 'no impact on geographies outside the United States where Vascepa is currently sold and/or under regulatory review.'

Financial news for AMRN dated on 2020-03-31: A Peek Into The Markets: US Stock Futures Gain Ahead Of Economic Data

Financial news for AMRN dated on 2020-03-31: Jefferies Downgrades Amarin Corp to Hold, Lowers Price Target to \$4

Financial news for AMRN dated on 2020-03-31: Amarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For Vascepa

Financial news for AMRN dated on 2020-03-30: Amarin Corporation Says Will Pursue All Available Remedies, Including an Appeal of Court's Decision in Vascepa Litigation

Financial news for AMRN dated on 2020-03-30: Amarin Loses Patent Battle; Traders Circulate Screenshot Appearing To Be Court Order From Case

Financial news for AMRN dated on 2020-03-30: '\$AMRN -- Will we get the Vascepa patent litigation decision today or tomorrow?' -Tweet From STAT News' Adam Feuerstein

Financial news for AMRN dated on 2020-03-17: Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals.

Financial news for AMRN dated on 2020-03-16: Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.

Financial news for AMRN dated on 2020-03-16: Amarin To Present Data Relevant To VASCEPA Capsules And 'Persistent Cardiovascular Risk' At American College of Cardiology's 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC), March 28-30

Financial news for AMRN dated on 2020-03-13: Benzinga's Top Upgrades, Downgrades For March 13, 2020

Financial news for AMRN dated on 2020-03-13: Goldman Sachs Upgrades Amarin Corp to Buy, Announces \$28 Price Target

Financial news for AMRN dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for AMRN dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for AMRN dated on 2020-03-11: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for AMRN dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for AMRN dated on 2020-03-10: Shares of several healthcare companies are trading higher as markets rebound following Monday's selloff. US President Trump on Monday indicated the US may implement payroll tax cuts and other measures to support the economy amid the coronavirus outbreak.

Financial news for AMRN dated on 2020-03-09: 52 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for AMRN dated on 2020-03-04: 36 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for AMRN dated on 2020-03-02: Amarin Corp PLC shares are trading higher after Cowen & Company initiated coverage on the stock with an Outperform rating and a price target of \$23 per share.

Financial news for AMRN dated on 2020-03-02: Cowen & Co. Initiates Coverage On Amarin Corp with Outperform Rating, Announces \$23 Price Target

Financial news for AMRN dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for AMRN dated on 2020-02-28: Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.

Financial news for AMRN dated on 2020-02-28: 50 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AMRN dated on 2020-02-28: 140 Biggest Movers From Yesterday

Financial news for AMRN dated on 2020-02-27: PreMarket Prep Stock Of The Day: Amarin

Financial news for AMRN dated on 2020-02-27: 100 Stocks Moving In Thursday's Mid-Day Session

Financial news for AMRN dated on 2020-02-27: Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.

Financial news for AMRN dated on 2020-02-27: 28 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for AMRN dated on 2020-02-27: 40 Stocks Moving in Thursday's Pre-Market Session

Financial news for AMRN dated on 2020-02-26: Amarin shares are trading lower after Oppenheimer maintained an Underperform rating on the stock and lowered its price target from \$13 to \$12 following earnings.

Financial news for AMRN dated on 2020-02-26: Oppenheimer Maintains Underperform on Amarin Corp, Lowers Price Target to \$12

Financial news for AMRN dated on 2020-02-25: Amarin Corp Q4 EPS \$0.04 Beats \$(0.02) Estimate, Sales \$142.044M Beat \$136.01M Estimate

Financial news for AMRN dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for AMRN dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for AMRN dated on 2020-02-18: Benzinga's Top Upgrades, Downgrades For February 18, 2020

Financial news for AMRN dated on 2020-02-18: Citigroup Upgrades Amarin Corp to Buy, Lowers Price Target to \$24

Financial news for AMRN dated on 2020-01-27: Amarin shares are trading lower in sympathy with the overall market as the Wuhan coronavirus continues to spread throughout the country, prompting travel bans in multiple Chinese cities. Reports say the death toll rose to 80 as of the end of Sunday.

Financial news for AMRN dated on 2020-01-23: UPDATE: Amarin Spokesperson On Co.'s Move To Expand Vascepa Coverage, Tells Benzinga 'While we are early in the process of our discussions with payers regarding the new indication, the response has been very positive'

Financial news for AMRN dated on 2020-01-23: UPDATE: Amarin Spokesperson Tells Benzinga 'Vascepa's new FDA-approved cardiovascular risk reduction indication has received a significant amount of attention,' Says Co. Sees Patient Access Improving Overall As Payers Adapt New Indication

Financial news for AMRN dated on 2020-01-23: Amarin Spokesperson Responds To Report Vascepa Added To Cigna National Coverage List, Declines Comment To Confirm/Deny, Tells Benzinga, 'We do not generally comment on changes in specific plans, as the access landscape can be very fluid'

Financial news for AMRN dated on 2020-01-22: Amarin Shares Rebound From Session Low,

Now Up 1% For Session; Traders Circulate Link From Cigna Website Showing Changes To Prescription Drug List, Co. Added Amarin's Vascepa To National Coverage List

Financial news for AMRN dated on 2020-01-21: Amarin shares are trading higher, not currently seeing any company-specific news. NOTE: Cantor Fitzgerald analysts noted the company 'looks like an even more interesting asset in a consolidating space' with an expanded label.'

Financial news for AMRN dated on 2020-01-13: 41 Stocks Moving In Monday's Mid-Day Session

Financial news for AMRN dated on 2020-01-13: Acasti Shares Slump On Failed Late-Stage Trial, Amarin Moves In Sympathy

Financial news for AMRN dated on 2020-01-13: 25 Stocks Moving in Monday's Pre-Market Session

Financial news for AMRN dated on 2020-01-10: 21 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AMRN dated on 2020-01-08: Amarin Corp Option Alert: Jan 17 \$20 Calls Sweep (12) near the Ask: 500 @ \$0.686 vs 38708 OI; Earnings 2/26 Before Open [est] Ref=\$18.93

Financial news for AMRN dated on 2020-01-08: Cantor Out Defending Amarin, Says Confirmed With Co. That UnitedHealth Designation Is 'Old News' And 'UNH has always been an outlier'

Financial news for AMRN dated on 2020-01-08: Amarin shares are trading lower after UnitedHealth deemed Vascepa a non-preferred drug as of January 20th.

Financial news for AMRN dated on 2020-01-08: Amarin Corp Option Alert: Feb 21 \$21 Calls Sweep (14) near the Bid: 1000 @ \$1.52 vs 10780 OI; Earnings 2/26 Before Open [est] Ref=\$19.4861

Financial news for AMRN dated on 2020-01-08: United Health Deems Vascepa A Non-Preferred Drug As Of Jan. 20

Financial news for AMRN dated on 2020-01-07: Amarin Sees Prelim. FY19 Sales At Or Slightly Above High End Of \$410M-\$425M Guidance Range; Sees FY20 Sales \$650M-\$700M vs \$687.48M Est.

Financial news for AMRN dated on 2020-01-06: JP Morgan Initiates Coverage On Amarin Corp with Neutral Rating, Announces \$22 Price Target

Financial news for AMRN dated on 2020-01-03: Amarin Corp Option Alert: Mar 20 \$30 Calls Sweep (17) near the Ask: 700 @ \$0.6 vs 9814 OI; Earnings 2/26 Before Open [est] Ref=\$20.78

Financial news for AMRN dated on 2020-01-03: 34 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for AMRN dated on 2020-01-02: The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe

Financial news for AMRN dated on 2020-01-02: 21 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for AMRN dated on 2020-01-02: 20 Stocks Moving in Thursday's Pre-Market Session

Financial news for AMRN dated on 2020-01-02: UPDATE: Amarin To Receive \$2.5M From HLS Therapeutics As A Results Of Canadian Approval For VASCEPA; HLS Expects VASCEPA Sales To Reach \$150M-\$250M Per Year

Financial news for AMRN dated on 2020-01-02: Amarin's VASCEPA Approved In Canada To Reduce The Risk Of Cardiovascular Events

Financial news for AMRN dated on 2019-12-28: Bulls And Bears Of The Week: Amazon, Apple, Boeing, Netflix, Tesla And More

Financial news for AMRN dated on 2019-12-24: Amarin Corp Option Alert: Jan 17 \$25 Calls Sweep (2) near the Ask: 1965 @ \$0.451 vs 51183 OI; Ref=\$21.1002

Financial news for AMRN dated on 2019-12-24: 10 Biotech M&A Targets Under The Scanner For 2020

Financial news for AMRN dated on 2019-12-23: A Perspective On Biopharma's Record M&A

Run In 2019

Financial news for AMRN dated on 2019-12-19: 36 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for AMRN dated on 2019-12-17: Amarin Corp shares are trading lower. Not seeing any news to justify the price action.

Financial news for AMRN dated on 2019-12-17: 19 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for AMRN dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for AMRN dated on 2019-12-16: Oppenheimer Earlier Maintained Underperform on Amarin Corp, Raised Price Target to \$8

Financial news for AMRN dated on 2019-12-16: Stocks That Hit 52-Week Highs On Monday

Financial news for AMRN dated on 2019-12-16: Stifel Downgrades Amarin Corp to Hold, Lowers Price Target to \$26

Financial news for AMRN dated on 2019-12-16: After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target

Financial news for AMRN dated on 2019-12-16: 24 Stocks Moving in Monday's Pre-Market Session

Financial news for AMRN dated on 2019-12-16: A Peek Into The Markets: US Stock Futures Up Ahead Of Economic Data

Financial news for AMRN dated on 2019-12-16: 5 Stocks To Watch For December 16, 2019

Financial news for AMRN dated on 2019-12-13: Amarin Sees 2019 VASCEPA Net Revenue \$410M-\$425M, Sees 2020 VASCEPA Net Revenue \$650M-\$700M

Financial news for AMRN dated on 2019-12-13: Amarin Receives FDA Approval Of VASCEPA To Reduce Cardiovascular Risk

Financial news for AMRN dated on 2019-12-13: Amarin Shares Halted, News Pending